Our research is focused on three disease areas:
- Neurodegenerative diseases (ALS, Alzheimer’s, Parkinson’s, Huntington’s), where we will leverage the success of our international consortium for ALS research, extending our work across a range of neurodegenerative diseases that have pathways in common with ALS.
- Neuropsychiatric diseases (autism, schizophrenia, bipolar), where we intend not only to extend our research of whole genomes of autism patients, but also expand into a range of related disorders, schizophrenia and bipolar, that have genes implicated in common with autism.
- Cancer, where we will push forward the leading edge of cancer genomics research by focusing on whole genome sequencing of individuals with cancer and their tumors, novel population-level cancer analytics, and the application of both single cell and spatial transcriptomics.
We will support these three disease-research areas with our ongoing commitment to technology innovation, particularly in single cell and spatial transcriptomics. This will include expanding our computational efforts dedicated to the analyses of these transcriptomic data, to population-level statistical analyses, and to the integration of these datasets.
We will also continue to support large-scale population genomic projects outside of our focused disease areas.
We look forward to working closely with the extraordinary scientific and clinical leadership among our faculty, staff scientists, Institutional Founding Members (IFMs) and other research partners to build new collaborations, and to jointly attract new public and private funding.
Please feel free to contact our project management team with any questions about projects, collaborations, grants, or other ways to become engaged with the NYGC.